Table 3 Univariate and multivariate analysis for overall survival in patient with high-risk myeloid neoplasm with S34F and Q157P mutations (n = 39).
Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
Age ≥70 years | 1.82 | 0.82–4.0 | 0.11 | – | – | – |
BM blast ≥ 20% vs 10–19% | 2.31 | 1.04–5.11 | 0.03 | 1.39 | 0.58–3.35 | 0.45 |
t-AML | 0.75 | 0.30–1.81 | 0.37 | |||
U2AF1 mutations: Q157P vs S34F | 2.64 | 1.08–6.47 | 0.008 | 4.37 | 1.31–14.11 | 0.01 |
CG abnormality | 1.37 | 0.59–3.15 | 0.46 | – | - | - |
ASXL1 | 2.69 | 1.05–6.86 | 0.008 | 0.49 | 0.15–1.56 | 0.23 |
BCOR | 0.48 | 0.19–1.20 | 0.12 | – | – | – |
RUNX1 | 1.24 | 0.47–3.29 | 0.65 | – | – | – |
TET2 | 0.83 | 0.30–2.29 | 0.72 | – | – | – |
DNMT3A | 0.49 | 0.30–1.69 | 0.72 | – | – | – |
RAS | 0.88 | 0.35–2.20 | 0.80 | – | – | – |
TP53 | 1.06 | 0.31–3.65 | 0.91 | – | – | – |
JAK2 | 4.90 | 0.24–98.1 | 0.01 | 8.12 | 1.39–47.31 | 0.02 |
SETBP1 | 0.38 | 0.10–1.40 | 0.32 | – | – | – |
FLT3 ITD | 2.47 | 0.42–14.46 | 0.11 | – | – | – |
Two or more co-mutations | 0.97 | 0.48–1.97 | 0.94 | – | – | – |
Treatment in high-risk MDS/AML | ||||||
3 + 7 | 0.66 | 0.35–1.26 | 0.71 | – | – | – |
HMA | 0.33 | 0.70–2.02 | 0.33 | – | – | – |
HMA plus venetoclax | 1.31 | 0.56–3.07 | 0.82 | – | – | – |
Complete remission (CR/CRi) | 0.77 | 0.38–1.55 | 0.47 | – | – | – |
Allo-HCT | 0.41 | 0.19–0.92 | 0.05 | 0.71 | 0.09–0.57 | 0.01 |
